Interferon (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Interferon" in English language version.

refsWebsite

Global rank English rank

125nih.gov

4^th place

79doi.org

2^nd place

19semanticscholar.org

11^th place

8^th place

16harvard.edu

18^th place

17^th place

3web.archive.org

1^st place

2worldcat.org

5^th place

2espacenet.com

800^th place

676^th place

1lexico.com

1,242^nd place

853^rd place

1hepctrust.org.uk

low place

1books.google.com

3^rd place

1nytimes.com

7^th place

1bnf.fr

124^th place

544^th place

bnf.fr

gallica.bnf.fr

Nagano Y, Kojima Y (October 1954). "[Immunizing property of vaccinia virus inactivated by ultraviolets rays]" [Immunizing property of vaccinia virus inactivated by ultraviolets rays]. Comptes Rendus des Séances de la Société de Biologie et de Ses Filiales (in French). 148 (19–20): 1700–1702. PMID 14364998.

books.google.com

Long SS, Pickering LK, Prober CG (2012). Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. p. 1502. ISBN 978-1437727029. Archived from the original on 2019-12-29. Retrieved 2017-09-01.

doi.org

De Andrea M, Ravera R, Gioia D, Gariglio M, Landolfo S (2002). "The interferon system: an overview". European Journal of Paediatric Neurology. 6 (6 Suppl A): A41–6, discussion A55–8. doi:10.1053/ejpn.2002.0573. PMID 12365360. S2CID 4523675.
Parkin J, Cohen B (June 2001). "An overview of the immune system". Lancet. 357 (9270): 1777–1789. doi:10.1016/S0140-6736(00)04904-7. PMID 11403834. S2CID 165986.
Elrefaey AM, Hollinghurst P, Reitmayer CM, Alphey L, Maringer K (October 2021). "Innate Immune Antagonism of Mosquito-Borne Flaviviruses in Humans and Mosquitoes". Viruses. 13 (11): 2116. doi:10.3390/v13112116. PMC 8624719. PMID 34834923.
de Weerd NA, Samarajiwa SA, Hertzog PJ (July 2007). "Type I interferon receptors: biochemistry and biological functions". The Journal of Biological Chemistry. 282 (28): 20053–20057. doi:10.1074/jbc.R700006200. PMID 17502368.
Liu YJ (2005). "IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors". Annual Review of Immunology. 23: 275–306. doi:10.1146/annurev.immunol.23.021704.115633. PMID 15771572.
Levy DE, Marié IJ, Durbin JE (December 2011). "Induction and function of type I and III interferon in response to viral infection". Current Opinion in Virology. 1 (6): 476–486. doi:10.1016/j.coviro.2011.11.001. PMC 3272644. PMID 22323926.
Kalliolias GD, Ivashkiv LB (2010). "Overview of the biology of type I interferons". Arthritis Research & Therapy. 12 (Suppl 1): S1. doi:10.1186/ar2881. PMC 2991774. PMID 20392288.
Hermant P, Michiels T (2014). "Interferon-λ in the context of viral infections: production, response and therapeutic implications". Journal of Innate Immunity. 6 (5): 563–574. doi:10.1159/000360084. PMC 6741612. PMID 24751921.
Espinosa V, Dutta O, McElrath C, Du P, Chang YJ, Cicciarelli B, et al. (October 2017). "Type III interferon is a critical regulator of innate antifungal immunity". Science Immunology. 2 (16): eaan5357. doi:10.1126/sciimmunol.aan5357. PMC 5880030. PMID 28986419.
Levy DE, Marié IJ, Durbin JE (2011). "Induction and function of type I and III interferon in response to viral infection". Current Opinion in Virology. 1 (6): 476–486. doi:10.1016/j.coviro.2011.11.001. ISSN 1879-6257. PMC 3272644. PMID 22323926.
Fensterl V, Sen GC (2009). "Interferons and viral infections". BioFactors. 35 (1): 14–20. doi:10.1002/biof.6. PMID 19319841. S2CID 27209861.
de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, et al. (June 2001). "Functional classification of interferon-stimulated genes identified using microarrays". Journal of Leukocyte Biology. 69 (6): 912–920. doi:10.1189/jlb.69.6.912. PMID 11404376. S2CID 1714991.
Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. (July 2003). "Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence". Nature. 424 (6948): 516–523. Bibcode:2003Natur.424..516T. doi:10.1038/nature01850. PMID 12872134.
Moiseeva O, Mallette FA, Mukhopadhyay UK, Moores A, Ferbeyre G (April 2006). "DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation". Molecular Biology of the Cell. 17 (4): 1583–1592. doi:10.1091/mbc.E05-09-0858. PMC 1415317. PMID 16436515.
Ikeda H, Old LJ, Schreiber RD (April 2002). "The roles of IFN gamma in protection against tumor development and cancer immunoediting". Cytokine & Growth Factor Reviews. 13 (2): 95–109. doi:10.1016/s1359-6101(01)00038-7. PMID 11900986.
Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. (July 2005). "A critical function for type I interferons in cancer immunoediting". Nature Immunology. 6 (7): 722–729. doi:10.1038/ni1213. PMID 15951814. S2CID 20374688.
Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. (December 2007). "Interferons at age 50: past, current and future impact on biomedicine". Nature Reviews. Drug Discovery. 6 (12): 975–990. doi:10.1038/nrd2422. PMC 7097588. PMID 18049472.
Whitehead KA, Dahlman JE, Langer RS, Anderson DG (2011). "Silencing or stimulation? siRNA delivery and the immune system". Annual Review of Chemical and Biomolecular Engineering. 2: 77–96. doi:10.1146/annurev-chembioeng-061010-114133. PMID 22432611. S2CID 28803811.
Haller O, Kochs G, Weber F (October–December 2007). "Interferon, Mx, and viral countermeasures". Cytokine & Growth Factor Reviews. 18 (5–6): 425–433. doi:10.1016/j.cytogfr.2007.06.001. PMC 7185553. PMID 17683972.
Platanias LC (May 2005). "Mechanisms of type-I- and type-II-interferon-mediated signalling". Nature Reviews. Immunology. 5 (5): 375–386. doi:10.1038/nri1604. PMID 15864272. S2CID 1472195.
Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ (January 2009). "INTERFEROME: the database of interferon regulated genes". Nucleic Acids Research. 37 (Database issue): D852 – D857. doi:10.1093/nar/gkn732. PMC 2686605. PMID 18996892.
Xu GP, Zhang ZL, Xiao S, Zhuang LK, Xia D, Zou QP, et al. (March 2013). "Rig-G negatively regulates SCF-E3 ligase activities by disrupting the assembly of COP9 signalosome complex". Biochemical and Biophysical Research Communications. 432 (3): 425–430. doi:10.1016/j.bbrc.2013.01.132. PMID 23415865.
Li D, Sun J, Liu W, Wang X, Bals R, Wu J, et al. (2016-10-04). "Rig-G is a growth inhibitory factor of lung cancer cells that suppresses STAT3 and NF-κB". Oncotarget. 7 (40): 66032–66050. doi:10.18632/oncotarget.11797. ISSN 1949-2553. PMC 5323212. PMID 27602766.
Navratil V, de Chassey B, Meyniel L, Pradezynski F, André P, Rabourdin-Combe C, et al. (July 2010). "System-level comparison of protein-protein interactions between viruses and the human type I interferon system network". Journal of Proteome Research. 9 (7): 3527–3536. doi:10.1021/pr100326j. PMID 20459142.
Lin RJ, Liao CL, Lin E, Lin YL (September 2004). "Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection". Journal of Virology. 78 (17): 9285–9294. doi:10.1128/JVI.78.17.9285-9294.2004. PMC 506928. PMID 15308723.
Sen GC (2001). "Viruses and interferons". Annual Review of Microbiology. 55: 255–281. doi:10.1146/annurev.micro.55.1.255. PMID 11544356.
Alcamí A, Symons JA, Smith GL (December 2000). "The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN". Journal of Virology. 74 (23): 11230–11239. doi:10.1128/JVI.74.23.11230-11239.2000. PMC 113220. PMID 11070021.
Minks MA, West DK, Benvin S, Baglioni C (October 1979). "Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells". The Journal of Biological Chemistry. 254 (20): 10180–10183. doi:10.1016/S0021-9258(19)86690-5. PMID 489592.
Miller JE, Samuel CE (September 1992). "Proteolytic cleavage of the reovirus sigma 3 protein results in enhanced double-stranded RNA-binding activity: identification of a repeated basic amino acid motif within the C-terminal binding region". Journal of Virology. 66 (9): 5347–5356. doi:10.1128/JVI.66.9.5347-5356.1992. PMC 289090. PMID 1501278.
Chang HW, Watson JC, Jacobs BL (June 1992). "The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase". Proceedings of the National Academy of Sciences of the United States of America. 89 (11): 4825–4829. Bibcode:1992PNAS...89.4825C. doi:10.1073/pnas.89.11.4825. PMC 49180. PMID 1350676.
Seo SH, Hoffmann E, Webster RG (September 2002). "Lethal H5N1 influenza viruses escape host anti-viral cytokine responses". Nature Medicine. 8 (9): 950–954. doi:10.1038/nm757. PMID 12195436. S2CID 8293109.
Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM (July 1999). "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein". Science. 285 (5424): 107–110. doi:10.1126/science.285.5424.107. PMID 10390359.
Taylor DR, Tian B, Romano PR, Hinnebusch AG, Lai MM, Mathews MB (February 2001). "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain". Journal of Virology. 75 (3): 1265–1273. doi:10.1128/JVI.75.3.1265-1273.2001. PMC 114032. PMID 11152499.
Abid K, Quadri R, Negro F (March 2000). "Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance". Science. 287 (5458): 1555. doi:10.1126/science.287.5458.1555a. PMID 10733410.
Pawlotsky JM (December 2003). "The nature of interferon-alpha resistance in hepatitis C virus infection". Current Opinion in Infectious Diseases. 16 (6): 587–592. doi:10.1097/00001432-200312000-00012. PMID 14624110. S2CID 72191620.
Sa Ribero M, Jouvenet N, Dreux M, Nisole S (July 2020). "Interplay between SARS-CoV-2 and the type I interferon response". PLOS Pathogens. 16 (7): e1008737. doi:10.1371/journal.ppat.1008737. PMC 7390284. PMID 32726355.
Palermo E, Di Carlo D, Sgarbanti M, Hiscott J (August 2021). "Type I Interferons in COVID-19 Pathogenesis". Biology. 10 (9): 829. doi:10.3390/biology10090829. PMC 8468334. PMID 34571706.
Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E (January 2021). "T-cell responses and therapies against SARS-CoV-2 infection". Immunology. 162 (1): 30–43. doi:10.1111/imm.13262. PMC 7730020. PMID 32935333.
Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E (September 2021). "SARS-CoV-2, COVID-19 and the Ageing Immune System". Nature Aging. 1 (9): 769–782. doi:10.1038/s43587-021-00114-7. PMC 8570568. PMID 34746804.
Park A, Iwasaki A (June 2020). "Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19". Cell Host & Microbe. 27 (6): 870–878. doi:10.1016/j.chom.2020.05.008. PMC 7255347. PMID 32464097.
Reis G, Moreira Silva EA, Medeiros Silva DC, Thabane L, Campos VH, Ferreira TS, et al. (February 2023). "Early Treatment with Pegylated Interferon Lambda for Covid-19". The New England Journal of Medicine. 388 (6): 518–528. doi:10.1056/NEJMoa2209760. PMC 9933926. PMID 36780676.
Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al. (2001). "Interferon in relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews. 2001 (4): CD002002. doi:10.1002/14651858.CD002002. PMC 7017973. PMID 11687131.
Goldstein D, Laszlo J (Sep 1988). "The role of interferon in cancer therapy: a current perspective". CA. 38 (5): 258–277. doi:10.3322/canjclin.38.5.258. PMID 2458171. S2CID 9160289.
Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, et al. (March 2008). "Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion". Cancer. 112 (5): 982–994. doi:10.1002/cncr.23251. PMID 18236459.
Shepherd J, Waugh N, Hewitson P (2000). "Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review". Health Technology Assessment. 4 (33): 1–67. doi:10.3310/hta4330. PMID 11134916.
Cunningham M, Foster GR (March 2012). "Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection". Therapeutic Advances in Gastroenterology. 5 (2): 139–151. doi:10.1177/1756283X11426895. PMC 3296085. PMID 22423262.
Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. (March 2011). "Boceprevir for untreated chronic HCV genotype 1 infection". The New England Journal of Medicine. 364 (13): 1195–1206. doi:10.1056/NEJMoa1010494. PMC 3766849. PMID 21449783.
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. (March 2011). "Boceprevir for previously treated chronic HCV genotype 1 infection". The New England Journal of Medicine. 364 (13): 1207–1217. doi:10.1056/NEJMoa1009482. PMC 3153125. PMID 21449784.
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. (May 2013). "Sofosbuvir for previously untreated chronic hepatitis C infection". The New England Journal of Medicine. 368 (20): 1878–1887. doi:10.1056/NEJMoa1214853. PMID 23607594.
Ishikawa T (October 2008). "Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients". World Journal of Gastroenterology. 14 (40): 6140–6144. doi:10.3748/wjg.14.6140. PMC 2761574. PMID 18985803.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. (October 2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. Bibcode:2009Natur.461..798T. doi:10.1038/nature08463. PMC 3172006. PMID 19759533.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. (September 2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. S2CID 1707096.
Wilhelmus KR (January 2015). "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis". The Cochrane Database of Systematic Reviews. 1 (1): CD002898. doi:10.1002/14651858.CD002898.pub5. PMC 4443501. PMID 25879115.
Bhatti Z, Berenson CS (February 2007). "Adult systemic cat scratch disease associated with therapy for hepatitis C". BMC Infectious Diseases. 7: 8. doi:10.1186/1471-2334-7-8. PMC 1810538. PMID 17319959.
Jamall IS, Yusuf S, Azhar M, Jamall S (November 2008). "Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?". World Journal of Gastroenterology. 14 (43): 6627–6631. doi:10.3748/wjg.14.6627. PMC 2773302. PMID 19034963.
Sharieff KA, Duncan D, Younossi Z (February 2002). "Advances in treatment of chronic hepatitis C: 'pegylated' interferons". Cleveland Clinic Journal of Medicine. 69 (2): 155–159. doi:10.3949/ccjm.69.2.155 (inactive 25 February 2025). PMID 11990646.{{cite journal}}: CS1 maint: DOI inactive as of February 2025 (link)
Stringfellow DA, Glasgow LA (August 1972). "Tilorone hydrochloride: an oral interferon-inducing agent". Antimicrobial Agents and Chemotherapy. 2 (2): 73–78. doi:10.1128/aac.2.2.73. PMC 444270. PMID 4670490.
Ekins S, Lingerfelt MA, Comer JE, Freiberg AN, Mirsalis JC, O'Loughlin K, et al. (February 2018). "Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection". Antimicrobial Agents and Chemotherapy. 62 (2). doi:10.1128/AAC.01711-17. PMC 5786809. PMID 29133569.
Isaacs A, Lindenmann J (September 1957). "Virus interference. I. The interferon". Proceedings of the Royal Society of London. Series B, Biological Sciences. 147 (927): 258–267. Bibcode:1957RSPSB.147..258I. doi:10.1098/rspb.1957.0048. PMID 13465720. S2CID 202574492.
Pestka S (July 2007). "The interferons: 50 years after their discovery, there is much more to learn". The Journal of Biological Chemistry. 282 (28): 20047–20051. doi:10.1074/jbc.R700004200. PMID 17502369.
Ho M, Enders JF (March 1959). "An Inhibitor of Viral Activity Appearing in Infected Cell Cultures". Proceedings of the National Academy of Sciences of the United States of America. 45 (3): 385–389. Bibcode:1959PNAS...45..385H. doi:10.1073/pnas.45.3.385. PMC 222571. PMID 16590396.
Tan YH, Tischfield J, Ruddle FH (February 1973). "The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21". The Journal of Experimental Medicine. 137 (2): 317–330. doi:10.1084/jem.137.2.317. PMC 2139494. PMID 4346649.
Tan YH (March 1976). "Chromosome 21 and the cell growth inhibitory effect of human interferon preparations". Nature. 260 (5547): 141–143. Bibcode:1976Natur.260..141T. doi:10.1038/260141a0. PMID 176593. S2CID 4287343.
Meager A, Graves H, Burke DC, Swallow DM (August 1979). "Involvement of a gene on chromosome 9 in human fibroblast interferon production". Nature. 280 (5722): 493–495. Bibcode:1979Natur.280..493M. doi:10.1038/280493a0. PMID 460428. S2CID 4315307.
Berthold W, Tan C, Tan YH (June 1978). "Chemical modifications of tyrosyl residue(s) and action of human-fibroblast interferon". European Journal of Biochemistry. 87 (2): 367–370. doi:10.1111/j.1432-1033.1978.tb12385.x. PMID 678325.
Berthold W, Tan C, Tan YH (July 1978). "Purification and in vitro labeling of interferon from a human fibroblastoid cell line". The Journal of Biological Chemistry. 253 (14): 5206–5212. doi:10.1016/S0021-9258(17)34678-1. PMID 670186.
Tan YH, Barakat F, Berthold W, Smith-Johannsen H, Tan C (August 1979). "The isolation and amino acid/sugar composition of human fibroblastoid interferon". The Journal of Biological Chemistry. 254 (16): 8067–8073. doi:10.1016/S0021-9258(18)36051-4. PMID 468807.
Zoon KC, Smith ME, Bridgen PJ, Anfinsen CB, Hunkapiller MW, Hood LE (February 1980). "Amino terminal sequence of the major component of human lymphoblastoid interferon". Science. 207 (4430): 527–528. Bibcode:1980Sci...207..527Z. doi:10.1126/science.7352260. PMID 7352260.
Okamura H, Berthold W, Hood L, Hunkapiller M, Inoue M, Smith-Johannsen H, et al. (August 1980). "Human fibroblastoid interferon: immunosorbent column chromatography and N-terminal amino acid sequence". Biochemistry. 19 (16): 3831–3835. doi:10.1021/bi00557a028. PMID 6157401.
Knight E, Hunkapiller MW, Korant BD, Hardy RW, Hood LE (February 1980). "Human fibroblast interferon: amino acid analysis and amino terminal amino acid sequence". Science. 207 (4430): 525–526. Bibcode:1980Sci...207..525K. doi:10.1126/science.7352259. PMID 7352259.
Weissenbach J, Chernajovsky Y, Zeevi M, Shulman L, Soreq H, Nir U, et al. (December 1980). "Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies". Proceedings of the National Academy of Sciences of the United States of America. 77 (12): 7152–7156. Bibcode:1980PNAS...77.7152W. doi:10.1073/pnas.77.12.7152. PMC 350459. PMID 6164058.
Taniguchi T, Fujii-Kuriyama Y, Muramatsu M (July 1980). "Molecular cloning of human interferon cDNA". Proceedings of the National Academy of Sciences of the United States of America. 77 (7): 4003–4006. Bibcode:1980PNAS...77.4003T. doi:10.1073/pnas.77.7.4003. PMC 349756. PMID 6159625.
Nagata S, Mantei N, Weissmann C (October 1980). "The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha". Nature. 287 (5781): 401–408. Bibcode:1980Natur.287..401N. doi:10.1038/287401a0. PMID 6159536. S2CID 29500779.
Gray PW, Goeddel DV (August 1982). "Structure of the human immune interferon gene". Nature. 298 (5877): 859–863. Bibcode:1982Natur.298..859G. doi:10.1038/298859a0. PMID 6180322. S2CID 4275528.
Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, et al. (March 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–320. Bibcode:1980Natur.284..316N. doi:10.1038/284316a0. PMID 6987533. S2CID 4310807.
Tan YH, Armstrong JA, Ke YH, Ho M (September 1970). "Regulation of cellular interferon production: enhancement by antimetabolites". Proceedings of the National Academy of Sciences of the United States of America. 67 (1): 464–471. Bibcode:1970PNAS...67..464T. doi:10.1073/pnas.67.1.464. PMC 283227. PMID 5272327.
Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC (December 2004). "Human interferons alpha, beta and omega". Growth Factors. 22 (4): 243–251. doi:10.1080/08977190400000833. PMID 15621727. S2CID 84918367.
Laghari ZA, Chen SN, Li L, Huang B, Gan Z, Zhou Y, et al. (July 2018). "Functional, signalling and transcriptional differences of three distinct type I IFNs in a perciform fish, the mandarin fish Siniperca chuatsi". Developmental and Comparative Immunology. 84 (1): 94–108. doi:10.1016/j.dci.2018.02.008. PMID 29432791. S2CID 3455413.
Boudinot P, Langevin C, Secombes CJ, Levraud JP (November 2016). "The Peculiar Characteristics of Fish Type I Interferons". Viruses. 8 (11): 298. doi:10.3390/v8110298. PMC 5127012. PMID 27827855.

espacenet.com

worldwide.espacenet.com

US patent 6207146, Tan YH, Hong WJ, "Gene expression in mammalian cells.", issued 27 April 2001, assigned to Institute of Molecular and Cell Biology
US patent 3773924, Ho M, Armstrong JA, Ke YH, Tan YH, "Interferon Production", issued 20 November 1973

harvard.edu

ui.adsabs.harvard.edu

Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. (July 2003). "Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence". Nature. 424 (6948): 516–523. Bibcode:2003Natur.424..516T. doi:10.1038/nature01850. PMID 12872134.
Chang HW, Watson JC, Jacobs BL (June 1992). "The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase". Proceedings of the National Academy of Sciences of the United States of America. 89 (11): 4825–4829. Bibcode:1992PNAS...89.4825C. doi:10.1073/pnas.89.11.4825. PMC 49180. PMID 1350676.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. (October 2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. Bibcode:2009Natur.461..798T. doi:10.1038/nature08463. PMC 3172006. PMID 19759533.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. (September 2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. S2CID 1707096.
Isaacs A, Lindenmann J (September 1957). "Virus interference. I. The interferon". Proceedings of the Royal Society of London. Series B, Biological Sciences. 147 (927): 258–267. Bibcode:1957RSPSB.147..258I. doi:10.1098/rspb.1957.0048. PMID 13465720. S2CID 202574492.
Ho M, Enders JF (March 1959). "An Inhibitor of Viral Activity Appearing in Infected Cell Cultures". Proceedings of the National Academy of Sciences of the United States of America. 45 (3): 385–389. Bibcode:1959PNAS...45..385H. doi:10.1073/pnas.45.3.385. PMC 222571. PMID 16590396.
Tan YH (March 1976). "Chromosome 21 and the cell growth inhibitory effect of human interferon preparations". Nature. 260 (5547): 141–143. Bibcode:1976Natur.260..141T. doi:10.1038/260141a0. PMID 176593. S2CID 4287343.
Meager A, Graves H, Burke DC, Swallow DM (August 1979). "Involvement of a gene on chromosome 9 in human fibroblast interferon production". Nature. 280 (5722): 493–495. Bibcode:1979Natur.280..493M. doi:10.1038/280493a0. PMID 460428. S2CID 4315307.
Zoon KC, Smith ME, Bridgen PJ, Anfinsen CB, Hunkapiller MW, Hood LE (February 1980). "Amino terminal sequence of the major component of human lymphoblastoid interferon". Science. 207 (4430): 527–528. Bibcode:1980Sci...207..527Z. doi:10.1126/science.7352260. PMID 7352260.
Knight E, Hunkapiller MW, Korant BD, Hardy RW, Hood LE (February 1980). "Human fibroblast interferon: amino acid analysis and amino terminal amino acid sequence". Science. 207 (4430): 525–526. Bibcode:1980Sci...207..525K. doi:10.1126/science.7352259. PMID 7352259.
Weissenbach J, Chernajovsky Y, Zeevi M, Shulman L, Soreq H, Nir U, et al. (December 1980). "Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies". Proceedings of the National Academy of Sciences of the United States of America. 77 (12): 7152–7156. Bibcode:1980PNAS...77.7152W. doi:10.1073/pnas.77.12.7152. PMC 350459. PMID 6164058.
Taniguchi T, Fujii-Kuriyama Y, Muramatsu M (July 1980). "Molecular cloning of human interferon cDNA". Proceedings of the National Academy of Sciences of the United States of America. 77 (7): 4003–4006. Bibcode:1980PNAS...77.4003T. doi:10.1073/pnas.77.7.4003. PMC 349756. PMID 6159625.
Nagata S, Mantei N, Weissmann C (October 1980). "The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha". Nature. 287 (5781): 401–408. Bibcode:1980Natur.287..401N. doi:10.1038/287401a0. PMID 6159536. S2CID 29500779.
Gray PW, Goeddel DV (August 1982). "Structure of the human immune interferon gene". Nature. 298 (5877): 859–863. Bibcode:1982Natur.298..859G. doi:10.1038/298859a0. PMID 6180322. S2CID 4275528.
Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, et al. (March 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–320. Bibcode:1980Natur.284..316N. doi:10.1038/284316a0. PMID 6987533. S2CID 4310807.
Tan YH, Armstrong JA, Ke YH, Ho M (September 1970). "Regulation of cellular interferon production: enhancement by antimetabolites". Proceedings of the National Academy of Sciences of the United States of America. 67 (1): 464–471. Bibcode:1970PNAS...67..464T. doi:10.1073/pnas.67.1.464. PMC 283227. PMID 5272327.

hepctrust.org.uk

"Genotypes of hepatitis C". Hepatitis C Trust. 2023. Retrieved 8 February 2023.

lexico.com

"Interferon | Definition of Interferon by Lexico". Archived from the original on 2020-12-22. Retrieved 2019-10-17.

nih.gov

pubmed.ncbi.nlm.nih.gov

De Andrea M, Ravera R, Gioia D, Gariglio M, Landolfo S (2002). "The interferon system: an overview". European Journal of Paediatric Neurology. 6 (6 Suppl A): A41–6, discussion A55–8. doi:10.1053/ejpn.2002.0573. PMID 12365360. S2CID 4523675.
Parkin J, Cohen B (June 2001). "An overview of the immune system". Lancet. 357 (9270): 1777–1789. doi:10.1016/S0140-6736(00)04904-7. PMID 11403834. S2CID 165986.
Elrefaey AM, Hollinghurst P, Reitmayer CM, Alphey L, Maringer K (October 2021). "Innate Immune Antagonism of Mosquito-Borne Flaviviruses in Humans and Mosquitoes". Viruses. 13 (11): 2116. doi:10.3390/v13112116. PMC 8624719. PMID 34834923.
de Weerd NA, Samarajiwa SA, Hertzog PJ (July 2007). "Type I interferon receptors: biochemistry and biological functions". The Journal of Biological Chemistry. 282 (28): 20053–20057. doi:10.1074/jbc.R700006200. PMID 17502368.
Liu YJ (2005). "IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors". Annual Review of Immunology. 23: 275–306. doi:10.1146/annurev.immunol.23.021704.115633. PMID 15771572.
Levy DE, Marié IJ, Durbin JE (December 2011). "Induction and function of type I and III interferon in response to viral infection". Current Opinion in Virology. 1 (6): 476–486. doi:10.1016/j.coviro.2011.11.001. PMC 3272644. PMID 22323926.
Kidd P (August 2003). "Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease". Alternative Medicine Review. 8 (3): 223–246. PMID 12946237.
Kalliolias GD, Ivashkiv LB (2010). "Overview of the biology of type I interferons". Arthritis Research & Therapy. 12 (Suppl 1): S1. doi:10.1186/ar2881. PMC 2991774. PMID 20392288.
Hermant P, Michiels T (2014). "Interferon-λ in the context of viral infections: production, response and therapeutic implications". Journal of Innate Immunity. 6 (5): 563–574. doi:10.1159/000360084. PMC 6741612. PMID 24751921.
Espinosa V, Dutta O, McElrath C, Du P, Chang YJ, Cicciarelli B, et al. (October 2017). "Type III interferon is a critical regulator of innate antifungal immunity". Science Immunology. 2 (16): eaan5357. doi:10.1126/sciimmunol.aan5357. PMC 5880030. PMID 28986419.
Levy DE, Marié IJ, Durbin JE (2011). "Induction and function of type I and III interferon in response to viral infection". Current Opinion in Virology. 1 (6): 476–486. doi:10.1016/j.coviro.2011.11.001. ISSN 1879-6257. PMC 3272644. PMID 22323926.
Fensterl V, Sen GC (2009). "Interferons and viral infections". BioFactors. 35 (1): 14–20. doi:10.1002/biof.6. PMID 19319841. S2CID 27209861.
de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, et al. (June 2001). "Functional classification of interferon-stimulated genes identified using microarrays". Journal of Leukocyte Biology. 69 (6): 912–920. doi:10.1189/jlb.69.6.912. PMID 11404376. S2CID 1714991.
Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. (July 2003). "Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence". Nature. 424 (6948): 516–523. Bibcode:2003Natur.424..516T. doi:10.1038/nature01850. PMID 12872134.
Moiseeva O, Mallette FA, Mukhopadhyay UK, Moores A, Ferbeyre G (April 2006). "DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation". Molecular Biology of the Cell. 17 (4): 1583–1592. doi:10.1091/mbc.E05-09-0858. PMC 1415317. PMID 16436515.
Ikeda H, Old LJ, Schreiber RD (April 2002). "The roles of IFN gamma in protection against tumor development and cancer immunoediting". Cytokine & Growth Factor Reviews. 13 (2): 95–109. doi:10.1016/s1359-6101(01)00038-7. PMID 11900986.
Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. (July 2005). "A critical function for type I interferons in cancer immunoediting". Nature Immunology. 6 (7): 722–729. doi:10.1038/ni1213. PMID 15951814. S2CID 20374688.
Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. (December 2007). "Interferons at age 50: past, current and future impact on biomedicine". Nature Reviews. Drug Discovery. 6 (12): 975–990. doi:10.1038/nrd2422. PMC 7097588. PMID 18049472.
Whitehead KA, Dahlman JE, Langer RS, Anderson DG (2011). "Silencing or stimulation? siRNA delivery and the immune system". Annual Review of Chemical and Biomolecular Engineering. 2: 77–96. doi:10.1146/annurev-chembioeng-061010-114133. PMID 22432611. S2CID 28803811.
Haller O, Kochs G, Weber F (October–December 2007). "Interferon, Mx, and viral countermeasures". Cytokine & Growth Factor Reviews. 18 (5–6): 425–433. doi:10.1016/j.cytogfr.2007.06.001. PMC 7185553. PMID 17683972.
Platanias LC (May 2005). "Mechanisms of type-I- and type-II-interferon-mediated signalling". Nature Reviews. Immunology. 5 (5): 375–386. doi:10.1038/nri1604. PMID 15864272. S2CID 1472195.
Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ (January 2009). "INTERFEROME: the database of interferon regulated genes". Nucleic Acids Research. 37 (Database issue): D852 – D857. doi:10.1093/nar/gkn732. PMC 2686605. PMID 18996892.
Xu GP, Zhang ZL, Xiao S, Zhuang LK, Xia D, Zou QP, et al. (March 2013). "Rig-G negatively regulates SCF-E3 ligase activities by disrupting the assembly of COP9 signalosome complex". Biochemical and Biophysical Research Communications. 432 (3): 425–430. doi:10.1016/j.bbrc.2013.01.132. PMID 23415865.
Li D, Sun J, Liu W, Wang X, Bals R, Wu J, et al. (2016-10-04). "Rig-G is a growth inhibitory factor of lung cancer cells that suppresses STAT3 and NF-κB". Oncotarget. 7 (40): 66032–66050. doi:10.18632/oncotarget.11797. ISSN 1949-2553. PMC 5323212. PMID 27602766.
Navratil V, de Chassey B, Meyniel L, Pradezynski F, André P, Rabourdin-Combe C, et al. (July 2010). "System-level comparison of protein-protein interactions between viruses and the human type I interferon system network". Journal of Proteome Research. 9 (7): 3527–3536. doi:10.1021/pr100326j. PMID 20459142.
Lin RJ, Liao CL, Lin E, Lin YL (September 2004). "Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection". Journal of Virology. 78 (17): 9285–9294. doi:10.1128/JVI.78.17.9285-9294.2004. PMC 506928. PMID 15308723.
Sen GC (2001). "Viruses and interferons". Annual Review of Microbiology. 55: 255–281. doi:10.1146/annurev.micro.55.1.255. PMID 11544356.
Alcamí A, Symons JA, Smith GL (December 2000). "The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN". Journal of Virology. 74 (23): 11230–11239. doi:10.1128/JVI.74.23.11230-11239.2000. PMC 113220. PMID 11070021.
Minks MA, West DK, Benvin S, Baglioni C (October 1979). "Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells". The Journal of Biological Chemistry. 254 (20): 10180–10183. doi:10.1016/S0021-9258(19)86690-5. PMID 489592.
Miller JE, Samuel CE (September 1992). "Proteolytic cleavage of the reovirus sigma 3 protein results in enhanced double-stranded RNA-binding activity: identification of a repeated basic amino acid motif within the C-terminal binding region". Journal of Virology. 66 (9): 5347–5356. doi:10.1128/JVI.66.9.5347-5356.1992. PMC 289090. PMID 1501278.
Chang HW, Watson JC, Jacobs BL (June 1992). "The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase". Proceedings of the National Academy of Sciences of the United States of America. 89 (11): 4825–4829. Bibcode:1992PNAS...89.4825C. doi:10.1073/pnas.89.11.4825. PMC 49180. PMID 1350676.
Seo SH, Hoffmann E, Webster RG (September 2002). "Lethal H5N1 influenza viruses escape host anti-viral cytokine responses". Nature Medicine. 8 (9): 950–954. doi:10.1038/nm757. PMID 12195436. S2CID 8293109.
Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM (July 1999). "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein". Science. 285 (5424): 107–110. doi:10.1126/science.285.5424.107. PMID 10390359.
Taylor DR, Tian B, Romano PR, Hinnebusch AG, Lai MM, Mathews MB (February 2001). "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain". Journal of Virology. 75 (3): 1265–1273. doi:10.1128/JVI.75.3.1265-1273.2001. PMC 114032. PMID 11152499.
Abid K, Quadri R, Negro F (March 2000). "Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance". Science. 287 (5458): 1555. doi:10.1126/science.287.5458.1555a. PMID 10733410.
Pawlotsky JM (December 2003). "The nature of interferon-alpha resistance in hepatitis C virus infection". Current Opinion in Infectious Diseases. 16 (6): 587–592. doi:10.1097/00001432-200312000-00012. PMID 14624110. S2CID 72191620.
Sa Ribero M, Jouvenet N, Dreux M, Nisole S (July 2020). "Interplay between SARS-CoV-2 and the type I interferon response". PLOS Pathogens. 16 (7): e1008737. doi:10.1371/journal.ppat.1008737. PMC 7390284. PMID 32726355.
Palermo E, Di Carlo D, Sgarbanti M, Hiscott J (August 2021). "Type I Interferons in COVID-19 Pathogenesis". Biology. 10 (9): 829. doi:10.3390/biology10090829. PMC 8468334. PMID 34571706.
Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E (January 2021). "T-cell responses and therapies against SARS-CoV-2 infection". Immunology. 162 (1): 30–43. doi:10.1111/imm.13262. PMC 7730020. PMID 32935333.
Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E (September 2021). "SARS-CoV-2, COVID-19 and the Ageing Immune System". Nature Aging. 1 (9): 769–782. doi:10.1038/s43587-021-00114-7. PMC 8570568. PMID 34746804.
Park A, Iwasaki A (June 2020). "Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19". Cell Host & Microbe. 27 (6): 870–878. doi:10.1016/j.chom.2020.05.008. PMC 7255347. PMID 32464097.
Reis G, Moreira Silva EA, Medeiros Silva DC, Thabane L, Campos VH, Ferreira TS, et al. (February 2023). "Early Treatment with Pegylated Interferon Lambda for Covid-19". The New England Journal of Medicine. 388 (6): 518–528. doi:10.1056/NEJMoa2209760. PMC 9933926. PMID 36780676.
Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al. (2001). "Interferon in relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews. 2001 (4): CD002002. doi:10.1002/14651858.CD002002. PMC 7017973. PMID 11687131.
Paolicelli D, Direnzo V, Trojano M (14 September 2009). "Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis". Biologics. 3: 369–376. PMC 2726074. PMID 19707422.
Goldstein D, Laszlo J (Sep 1988). "The role of interferon in cancer therapy: a current perspective". CA. 38 (5): 258–277. doi:10.3322/canjclin.38.5.258. PMID 2458171. S2CID 9160289.
Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, et al. (March 2008). "Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion". Cancer. 112 (5): 982–994. doi:10.1002/cncr.23251. PMID 18236459.
Cooksley WG (March 2004). "The role of interferon therapy in hepatitis B". MedGenMed. 6 (1): 16. PMC 1140699. PMID 15208528.
Shepherd J, Waugh N, Hewitson P (2000). "Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review". Health Technology Assessment. 4 (33): 1–67. doi:10.3310/hta4330. PMID 11134916.
Cunningham M, Foster GR (March 2012). "Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection". Therapeutic Advances in Gastroenterology. 5 (2): 139–151. doi:10.1177/1756283X11426895. PMC 3296085. PMID 22423262.
Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. (March 2011). "Boceprevir for untreated chronic HCV genotype 1 infection". The New England Journal of Medicine. 364 (13): 1195–1206. doi:10.1056/NEJMoa1010494. PMC 3766849. PMID 21449783.
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. (March 2011). "Boceprevir for previously treated chronic HCV genotype 1 infection". The New England Journal of Medicine. 364 (13): 1207–1217. doi:10.1056/NEJMoa1009482. PMC 3153125. PMID 21449784.
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. (May 2013). "Sofosbuvir for previously untreated chronic hepatitis C infection". The New England Journal of Medicine. 368 (20): 1878–1887. doi:10.1056/NEJMoa1214853. PMID 23607594.
Ishikawa T (October 2008). "Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients". World Journal of Gastroenterology. 14 (40): 6140–6144. doi:10.3748/wjg.14.6140. PMC 2761574. PMID 18985803.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. (October 2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. Bibcode:2009Natur.461..798T. doi:10.1038/nature08463. PMC 3172006. PMID 19759533.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. (September 2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. S2CID 1707096.
Wilhelmus KR (January 2015). "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis". The Cochrane Database of Systematic Reviews. 1 (1): CD002898. doi:10.1002/14651858.CD002898.pub5. PMC 4443501. PMID 25879115.
Bhatti Z, Berenson CS (February 2007). "Adult systemic cat scratch disease associated with therapy for hepatitis C". BMC Infectious Diseases. 7: 8. doi:10.1186/1471-2334-7-8. PMC 1810538. PMID 17319959.
Jamall IS, Yusuf S, Azhar M, Jamall S (November 2008). "Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?". World Journal of Gastroenterology. 14 (43): 6627–6631. doi:10.3748/wjg.14.6627. PMC 2773302. PMID 19034963.
"NIH Consensus Statement on Management of Hepatitis C: 2002". NIH Consensus and State-of-the-Science Statements. 19 (3): 1–46. 2002. PMID 14768714.
Sharieff KA, Duncan D, Younossi Z (February 2002). "Advances in treatment of chronic hepatitis C: 'pegylated' interferons". Cleveland Clinic Journal of Medicine. 69 (2): 155–159. doi:10.3949/ccjm.69.2.155 (inactive 25 February 2025). PMID 11990646.{{cite journal}}: CS1 maint: DOI inactive as of February 2025 (link)
Stringfellow DA, Glasgow LA (August 1972). "Tilorone hydrochloride: an oral interferon-inducing agent". Antimicrobial Agents and Chemotherapy. 2 (2): 73–78. doi:10.1128/aac.2.2.73. PMC 444270. PMID 4670490.
Ekins S, Lingerfelt MA, Comer JE, Freiberg AN, Mirsalis JC, O'Loughlin K, et al. (February 2018). "Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection". Antimicrobial Agents and Chemotherapy. 62 (2). doi:10.1128/AAC.01711-17. PMC 5786809. PMID 29133569.
Isaacs A, Lindenmann J (September 1957). "Virus interference. I. The interferon". Proceedings of the Royal Society of London. Series B, Biological Sciences. 147 (927): 258–267. Bibcode:1957RSPSB.147..258I. doi:10.1098/rspb.1957.0048. PMID 13465720. S2CID 202574492.
Pestka S (July 2007). "The interferons: 50 years after their discovery, there is much more to learn". The Journal of Biological Chemistry. 282 (28): 20047–20051. doi:10.1074/jbc.R700004200. PMID 17502369.
Nagano Y, Kojima Y (October 1954). "[Immunizing property of vaccinia virus inactivated by ultraviolets rays]" [Immunizing property of vaccinia virus inactivated by ultraviolets rays]. Comptes Rendus des Séances de la Société de Biologie et de Ses Filiales (in French). 148 (19–20): 1700–1702. PMID 14364998.
Ho M, Enders JF (March 1959). "An Inhibitor of Viral Activity Appearing in Infected Cell Cultures". Proceedings of the National Academy of Sciences of the United States of America. 45 (3): 385–389. Bibcode:1959PNAS...45..385H. doi:10.1073/pnas.45.3.385. PMC 222571. PMID 16590396.
Tan YH, Tischfield J, Ruddle FH (February 1973). "The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21". The Journal of Experimental Medicine. 137 (2): 317–330. doi:10.1084/jem.137.2.317. PMC 2139494. PMID 4346649.
Tan YH (March 1976). "Chromosome 21 and the cell growth inhibitory effect of human interferon preparations". Nature. 260 (5547): 141–143. Bibcode:1976Natur.260..141T. doi:10.1038/260141a0. PMID 176593. S2CID 4287343.
Meager A, Graves H, Burke DC, Swallow DM (August 1979). "Involvement of a gene on chromosome 9 in human fibroblast interferon production". Nature. 280 (5722): 493–495. Bibcode:1979Natur.280..493M. doi:10.1038/280493a0. PMID 460428. S2CID 4315307.
Berthold W, Tan C, Tan YH (June 1978). "Chemical modifications of tyrosyl residue(s) and action of human-fibroblast interferon". European Journal of Biochemistry. 87 (2): 367–370. doi:10.1111/j.1432-1033.1978.tb12385.x. PMID 678325.
Berthold W, Tan C, Tan YH (July 1978). "Purification and in vitro labeling of interferon from a human fibroblastoid cell line". The Journal of Biological Chemistry. 253 (14): 5206–5212. doi:10.1016/S0021-9258(17)34678-1. PMID 670186.
Tan YH, Barakat F, Berthold W, Smith-Johannsen H, Tan C (August 1979). "The isolation and amino acid/sugar composition of human fibroblastoid interferon". The Journal of Biological Chemistry. 254 (16): 8067–8073. doi:10.1016/S0021-9258(18)36051-4. PMID 468807.
Zoon KC, Smith ME, Bridgen PJ, Anfinsen CB, Hunkapiller MW, Hood LE (February 1980). "Amino terminal sequence of the major component of human lymphoblastoid interferon". Science. 207 (4430): 527–528. Bibcode:1980Sci...207..527Z. doi:10.1126/science.7352260. PMID 7352260.
Okamura H, Berthold W, Hood L, Hunkapiller M, Inoue M, Smith-Johannsen H, et al. (August 1980). "Human fibroblastoid interferon: immunosorbent column chromatography and N-terminal amino acid sequence". Biochemistry. 19 (16): 3831–3835. doi:10.1021/bi00557a028. PMID 6157401.
Knight E, Hunkapiller MW, Korant BD, Hardy RW, Hood LE (February 1980). "Human fibroblast interferon: amino acid analysis and amino terminal amino acid sequence". Science. 207 (4430): 525–526. Bibcode:1980Sci...207..525K. doi:10.1126/science.7352259. PMID 7352259.
Weissenbach J, Chernajovsky Y, Zeevi M, Shulman L, Soreq H, Nir U, et al. (December 1980). "Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies". Proceedings of the National Academy of Sciences of the United States of America. 77 (12): 7152–7156. Bibcode:1980PNAS...77.7152W. doi:10.1073/pnas.77.12.7152. PMC 350459. PMID 6164058.
Taniguchi T, Fujii-Kuriyama Y, Muramatsu M (July 1980). "Molecular cloning of human interferon cDNA". Proceedings of the National Academy of Sciences of the United States of America. 77 (7): 4003–4006. Bibcode:1980PNAS...77.4003T. doi:10.1073/pnas.77.7.4003. PMC 349756. PMID 6159625.
Nagata S, Mantei N, Weissmann C (October 1980). "The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha". Nature. 287 (5781): 401–408. Bibcode:1980Natur.287..401N. doi:10.1038/287401a0. PMID 6159536. S2CID 29500779.
Gray PW, Goeddel DV (August 1982). "Structure of the human immune interferon gene". Nature. 298 (5877): 859–863. Bibcode:1982Natur.298..859G. doi:10.1038/298859a0. PMID 6180322. S2CID 4275528.
Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, et al. (March 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–320. Bibcode:1980Natur.284..316N. doi:10.1038/284316a0. PMID 6987533. S2CID 4310807.
Tan YH, Armstrong JA, Ke YH, Ho M (September 1970). "Regulation of cellular interferon production: enhancement by antimetabolites". Proceedings of the National Academy of Sciences of the United States of America. 67 (1): 464–471. Bibcode:1970PNAS...67..464T. doi:10.1073/pnas.67.1.464. PMC 283227. PMID 5272327.
Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC (December 2004). "Human interferons alpha, beta and omega". Growth Factors. 22 (4): 243–251. doi:10.1080/08977190400000833. PMID 15621727. S2CID 84918367.
Laghari ZA, Chen SN, Li L, Huang B, Gan Z, Zhou Y, et al. (July 2018). "Functional, signalling and transcriptional differences of three distinct type I IFNs in a perciform fish, the mandarin fish Siniperca chuatsi". Developmental and Comparative Immunology. 84 (1): 94–108. doi:10.1016/j.dci.2018.02.008. PMID 29432791. S2CID 3455413.
Boudinot P, Langevin C, Secombes CJ, Levraud JP (November 2016). "The Peculiar Characteristics of Fish Type I Interferons". Viruses. 8 (11): 298. doi:10.3390/v8110298. PMC 5127012. PMID 27827855.

ncbi.nlm.nih.gov

Elrefaey AM, Hollinghurst P, Reitmayer CM, Alphey L, Maringer K (October 2021). "Innate Immune Antagonism of Mosquito-Borne Flaviviruses in Humans and Mosquitoes". Viruses. 13 (11): 2116. doi:10.3390/v13112116. PMC 8624719. PMID 34834923.
Levy DE, Marié IJ, Durbin JE (December 2011). "Induction and function of type I and III interferon in response to viral infection". Current Opinion in Virology. 1 (6): 476–486. doi:10.1016/j.coviro.2011.11.001. PMC 3272644. PMID 22323926.
Kalliolias GD, Ivashkiv LB (2010). "Overview of the biology of type I interferons". Arthritis Research & Therapy. 12 (Suppl 1): S1. doi:10.1186/ar2881. PMC 2991774. PMID 20392288.
Hermant P, Michiels T (2014). "Interferon-λ in the context of viral infections: production, response and therapeutic implications". Journal of Innate Immunity. 6 (5): 563–574. doi:10.1159/000360084. PMC 6741612. PMID 24751921.
Espinosa V, Dutta O, McElrath C, Du P, Chang YJ, Cicciarelli B, et al. (October 2017). "Type III interferon is a critical regulator of innate antifungal immunity". Science Immunology. 2 (16): eaan5357. doi:10.1126/sciimmunol.aan5357. PMC 5880030. PMID 28986419.
Levy DE, Marié IJ, Durbin JE (2011). "Induction and function of type I and III interferon in response to viral infection". Current Opinion in Virology. 1 (6): 476–486. doi:10.1016/j.coviro.2011.11.001. ISSN 1879-6257. PMC 3272644. PMID 22323926.
Moiseeva O, Mallette FA, Mukhopadhyay UK, Moores A, Ferbeyre G (April 2006). "DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation". Molecular Biology of the Cell. 17 (4): 1583–1592. doi:10.1091/mbc.E05-09-0858. PMC 1415317. PMID 16436515.
Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. (December 2007). "Interferons at age 50: past, current and future impact on biomedicine". Nature Reviews. Drug Discovery. 6 (12): 975–990. doi:10.1038/nrd2422. PMC 7097588. PMID 18049472.
Haller O, Kochs G, Weber F (October–December 2007). "Interferon, Mx, and viral countermeasures". Cytokine & Growth Factor Reviews. 18 (5–6): 425–433. doi:10.1016/j.cytogfr.2007.06.001. PMC 7185553. PMID 17683972.
Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ (January 2009). "INTERFEROME: the database of interferon regulated genes". Nucleic Acids Research. 37 (Database issue): D852 – D857. doi:10.1093/nar/gkn732. PMC 2686605. PMID 18996892.
Li D, Sun J, Liu W, Wang X, Bals R, Wu J, et al. (2016-10-04). "Rig-G is a growth inhibitory factor of lung cancer cells that suppresses STAT3 and NF-κB". Oncotarget. 7 (40): 66032–66050. doi:10.18632/oncotarget.11797. ISSN 1949-2553. PMC 5323212. PMID 27602766.
Lin RJ, Liao CL, Lin E, Lin YL (September 2004). "Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection". Journal of Virology. 78 (17): 9285–9294. doi:10.1128/JVI.78.17.9285-9294.2004. PMC 506928. PMID 15308723.
Alcamí A, Symons JA, Smith GL (December 2000). "The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN". Journal of Virology. 74 (23): 11230–11239. doi:10.1128/JVI.74.23.11230-11239.2000. PMC 113220. PMID 11070021.
Miller JE, Samuel CE (September 1992). "Proteolytic cleavage of the reovirus sigma 3 protein results in enhanced double-stranded RNA-binding activity: identification of a repeated basic amino acid motif within the C-terminal binding region". Journal of Virology. 66 (9): 5347–5356. doi:10.1128/JVI.66.9.5347-5356.1992. PMC 289090. PMID 1501278.
Chang HW, Watson JC, Jacobs BL (June 1992). "The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase". Proceedings of the National Academy of Sciences of the United States of America. 89 (11): 4825–4829. Bibcode:1992PNAS...89.4825C. doi:10.1073/pnas.89.11.4825. PMC 49180. PMID 1350676.
Taylor DR, Tian B, Romano PR, Hinnebusch AG, Lai MM, Mathews MB (February 2001). "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain". Journal of Virology. 75 (3): 1265–1273. doi:10.1128/JVI.75.3.1265-1273.2001. PMC 114032. PMID 11152499.
Sa Ribero M, Jouvenet N, Dreux M, Nisole S (July 2020). "Interplay between SARS-CoV-2 and the type I interferon response". PLOS Pathogens. 16 (7): e1008737. doi:10.1371/journal.ppat.1008737. PMC 7390284. PMID 32726355.
Palermo E, Di Carlo D, Sgarbanti M, Hiscott J (August 2021). "Type I Interferons in COVID-19 Pathogenesis". Biology. 10 (9): 829. doi:10.3390/biology10090829. PMC 8468334. PMID 34571706.
Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E (January 2021). "T-cell responses and therapies against SARS-CoV-2 infection". Immunology. 162 (1): 30–43. doi:10.1111/imm.13262. PMC 7730020. PMID 32935333.
Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E (September 2021). "SARS-CoV-2, COVID-19 and the Ageing Immune System". Nature Aging. 1 (9): 769–782. doi:10.1038/s43587-021-00114-7. PMC 8570568. PMID 34746804.
Park A, Iwasaki A (June 2020). "Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19". Cell Host & Microbe. 27 (6): 870–878. doi:10.1016/j.chom.2020.05.008. PMC 7255347. PMID 32464097.
Reis G, Moreira Silva EA, Medeiros Silva DC, Thabane L, Campos VH, Ferreira TS, et al. (February 2023). "Early Treatment with Pegylated Interferon Lambda for Covid-19". The New England Journal of Medicine. 388 (6): 518–528. doi:10.1056/NEJMoa2209760. PMC 9933926. PMID 36780676.
Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al. (2001). "Interferon in relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews. 2001 (4): CD002002. doi:10.1002/14651858.CD002002. PMC 7017973. PMID 11687131.
Paolicelli D, Direnzo V, Trojano M (14 September 2009). "Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis". Biologics. 3: 369–376. PMC 2726074. PMID 19707422.
Cooksley WG (March 2004). "The role of interferon therapy in hepatitis B". MedGenMed. 6 (1): 16. PMC 1140699. PMID 15208528.
Cunningham M, Foster GR (March 2012). "Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection". Therapeutic Advances in Gastroenterology. 5 (2): 139–151. doi:10.1177/1756283X11426895. PMC 3296085. PMID 22423262.
Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. (March 2011). "Boceprevir for untreated chronic HCV genotype 1 infection". The New England Journal of Medicine. 364 (13): 1195–1206. doi:10.1056/NEJMoa1010494. PMC 3766849. PMID 21449783.
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. (March 2011). "Boceprevir for previously treated chronic HCV genotype 1 infection". The New England Journal of Medicine. 364 (13): 1207–1217. doi:10.1056/NEJMoa1009482. PMC 3153125. PMID 21449784.
Ishikawa T (October 2008). "Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients". World Journal of Gastroenterology. 14 (40): 6140–6144. doi:10.3748/wjg.14.6140. PMC 2761574. PMID 18985803.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. (October 2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. Bibcode:2009Natur.461..798T. doi:10.1038/nature08463. PMC 3172006. PMID 19759533.
Wilhelmus KR (January 2015). "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis". The Cochrane Database of Systematic Reviews. 1 (1): CD002898. doi:10.1002/14651858.CD002898.pub5. PMC 4443501. PMID 25879115.
Bhatti Z, Berenson CS (February 2007). "Adult systemic cat scratch disease associated with therapy for hepatitis C". BMC Infectious Diseases. 7: 8. doi:10.1186/1471-2334-7-8. PMC 1810538. PMID 17319959.
Jamall IS, Yusuf S, Azhar M, Jamall S (November 2008). "Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?". World Journal of Gastroenterology. 14 (43): 6627–6631. doi:10.3748/wjg.14.6627. PMC 2773302. PMID 19034963.
Stringfellow DA, Glasgow LA (August 1972). "Tilorone hydrochloride: an oral interferon-inducing agent". Antimicrobial Agents and Chemotherapy. 2 (2): 73–78. doi:10.1128/aac.2.2.73. PMC 444270. PMID 4670490.
Ekins S, Lingerfelt MA, Comer JE, Freiberg AN, Mirsalis JC, O'Loughlin K, et al. (February 2018). "Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection". Antimicrobial Agents and Chemotherapy. 62 (2). doi:10.1128/AAC.01711-17. PMC 5786809. PMID 29133569.
Ho M, Enders JF (March 1959). "An Inhibitor of Viral Activity Appearing in Infected Cell Cultures". Proceedings of the National Academy of Sciences of the United States of America. 45 (3): 385–389. Bibcode:1959PNAS...45..385H. doi:10.1073/pnas.45.3.385. PMC 222571. PMID 16590396.
Tan YH, Tischfield J, Ruddle FH (February 1973). "The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21". The Journal of Experimental Medicine. 137 (2): 317–330. doi:10.1084/jem.137.2.317. PMC 2139494. PMID 4346649.
Weissenbach J, Chernajovsky Y, Zeevi M, Shulman L, Soreq H, Nir U, et al. (December 1980). "Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies". Proceedings of the National Academy of Sciences of the United States of America. 77 (12): 7152–7156. Bibcode:1980PNAS...77.7152W. doi:10.1073/pnas.77.12.7152. PMC 350459. PMID 6164058.
Taniguchi T, Fujii-Kuriyama Y, Muramatsu M (July 1980). "Molecular cloning of human interferon cDNA". Proceedings of the National Academy of Sciences of the United States of America. 77 (7): 4003–4006. Bibcode:1980PNAS...77.4003T. doi:10.1073/pnas.77.7.4003. PMC 349756. PMID 6159625.
Tan YH, Armstrong JA, Ke YH, Ho M (September 1970). "Regulation of cellular interferon production: enhancement by antimetabolites". Proceedings of the National Academy of Sciences of the United States of America. 67 (1): 464–471. Bibcode:1970PNAS...67..464T. doi:10.1073/pnas.67.1.464. PMC 283227. PMID 5272327.
Boudinot P, Langevin C, Secombes CJ, Levraud JP (November 2016). "The Peculiar Characteristics of Fish Type I Interferons". Viruses. 8 (11): 298. doi:10.3390/v8110298. PMC 5127012. PMID 27827855.

nytimes.com

Kolata G (2015-01-22). "Jean Lindenmann, Who Made Interferon His Life's Work, Is Dead at 90". The New York Times. Archived from the original on 2019-12-27. Retrieved 2015-02-12.

semanticscholar.org

api.semanticscholar.org

De Andrea M, Ravera R, Gioia D, Gariglio M, Landolfo S (2002). "The interferon system: an overview". European Journal of Paediatric Neurology. 6 (6 Suppl A): A41–6, discussion A55–8. doi:10.1053/ejpn.2002.0573. PMID 12365360. S2CID 4523675.
Parkin J, Cohen B (June 2001). "An overview of the immune system". Lancet. 357 (9270): 1777–1789. doi:10.1016/S0140-6736(00)04904-7. PMID 11403834. S2CID 165986.
Fensterl V, Sen GC (2009). "Interferons and viral infections". BioFactors. 35 (1): 14–20. doi:10.1002/biof.6. PMID 19319841. S2CID 27209861.
de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, et al. (June 2001). "Functional classification of interferon-stimulated genes identified using microarrays". Journal of Leukocyte Biology. 69 (6): 912–920. doi:10.1189/jlb.69.6.912. PMID 11404376. S2CID 1714991.
Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. (July 2005). "A critical function for type I interferons in cancer immunoediting". Nature Immunology. 6 (7): 722–729. doi:10.1038/ni1213. PMID 15951814. S2CID 20374688.
Whitehead KA, Dahlman JE, Langer RS, Anderson DG (2011). "Silencing or stimulation? siRNA delivery and the immune system". Annual Review of Chemical and Biomolecular Engineering. 2: 77–96. doi:10.1146/annurev-chembioeng-061010-114133. PMID 22432611. S2CID 28803811.
Platanias LC (May 2005). "Mechanisms of type-I- and type-II-interferon-mediated signalling". Nature Reviews. Immunology. 5 (5): 375–386. doi:10.1038/nri1604. PMID 15864272. S2CID 1472195.
Seo SH, Hoffmann E, Webster RG (September 2002). "Lethal H5N1 influenza viruses escape host anti-viral cytokine responses". Nature Medicine. 8 (9): 950–954. doi:10.1038/nm757. PMID 12195436. S2CID 8293109.
Pawlotsky JM (December 2003). "The nature of interferon-alpha resistance in hepatitis C virus infection". Current Opinion in Infectious Diseases. 16 (6): 587–592. doi:10.1097/00001432-200312000-00012. PMID 14624110. S2CID 72191620.
Goldstein D, Laszlo J (Sep 1988). "The role of interferon in cancer therapy: a current perspective". CA. 38 (5): 258–277. doi:10.3322/canjclin.38.5.258. PMID 2458171. S2CID 9160289.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. (September 2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. S2CID 1707096.
Isaacs A, Lindenmann J (September 1957). "Virus interference. I. The interferon". Proceedings of the Royal Society of London. Series B, Biological Sciences. 147 (927): 258–267. Bibcode:1957RSPSB.147..258I. doi:10.1098/rspb.1957.0048. PMID 13465720. S2CID 202574492.
Tan YH (March 1976). "Chromosome 21 and the cell growth inhibitory effect of human interferon preparations". Nature. 260 (5547): 141–143. Bibcode:1976Natur.260..141T. doi:10.1038/260141a0. PMID 176593. S2CID 4287343.
Meager A, Graves H, Burke DC, Swallow DM (August 1979). "Involvement of a gene on chromosome 9 in human fibroblast interferon production". Nature. 280 (5722): 493–495. Bibcode:1979Natur.280..493M. doi:10.1038/280493a0. PMID 460428. S2CID 4315307.
Nagata S, Mantei N, Weissmann C (October 1980). "The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha". Nature. 287 (5781): 401–408. Bibcode:1980Natur.287..401N. doi:10.1038/287401a0. PMID 6159536. S2CID 29500779.
Gray PW, Goeddel DV (August 1982). "Structure of the human immune interferon gene". Nature. 298 (5877): 859–863. Bibcode:1982Natur.298..859G. doi:10.1038/298859a0. PMID 6180322. S2CID 4275528.
Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, et al. (March 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–320. Bibcode:1980Natur.284..316N. doi:10.1038/284316a0. PMID 6987533. S2CID 4310807.
Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC (December 2004). "Human interferons alpha, beta and omega". Growth Factors. 22 (4): 243–251. doi:10.1080/08977190400000833. PMID 15621727. S2CID 84918367.
Laghari ZA, Chen SN, Li L, Huang B, Gan Z, Zhou Y, et al. (July 2018). "Functional, signalling and transcriptional differences of three distinct type I IFNs in a perciform fish, the mandarin fish Siniperca chuatsi". Developmental and Comparative Immunology. 84 (1): 94–108. doi:10.1016/j.dci.2018.02.008. PMID 29432791. S2CID 3455413.

web.archive.org

"Interferon | Definition of Interferon by Lexico". Archived from the original on 2020-12-22. Retrieved 2019-10-17.
Long SS, Pickering LK, Prober CG (2012). Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. p. 1502. ISBN 978-1437727029. Archived from the original on 2019-12-29. Retrieved 2017-09-01.
Kolata G (2015-01-22). "Jean Lindenmann, Who Made Interferon His Life's Work, Is Dead at 90". The New York Times. Archived from the original on 2019-12-27. Retrieved 2015-02-12.

worldcat.org

search.worldcat.org

Levy DE, Marié IJ, Durbin JE (2011). "Induction and function of type I and III interferon in response to viral infection". Current Opinion in Virology. 1 (6): 476–486. doi:10.1016/j.coviro.2011.11.001. ISSN 1879-6257. PMC 3272644. PMID 22323926.
Li D, Sun J, Liu W, Wang X, Bals R, Wu J, et al. (2016-10-04). "Rig-G is a growth inhibitory factor of lung cancer cells that suppresses STAT3 and NF-κB". Oncotarget. 7 (40): 66032–66050. doi:10.18632/oncotarget.11797. ISSN 1949-2553. PMC 5323212. PMID 27602766.